09/28/23 8:00 AMNasdaq : CLNN Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action Clene Inc. (Nasdaq: CLNN) through its wholly owned subsidiary Clene NanomedicineRHEA-AIneutral
09/25/23 4:00 PMNasdaq : CLNN conferencesClene to Present at Cantor Fitzgerald Annual Global Healthcare ConferenceClene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal functionRHEA-AIneutral
09/25/23 7:00 AMNasdaq : CLNN Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical ControlsProlonged life with 49% decreased risk of death for participants in the HEALEY ALS Platform Trial treated with CNM-Au8 ® 30mg compared to PRO-ACT matched placebo over long-term follow-up, p=0.046 Prolonged life with 59% decreased risk of death for participants in an integrated meta-analysis acrossRHEA-AIneutral
08/30/23 8:20 AMNasdaq : CLNN conferencesClene to Present at Upcoming September ConferencesClene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function toRHEA-AIneutral
08/29/23 7:00 AMNasdaq : CLNN Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-UpCleneRHEA-AIneutral
08/14/23 8:00 AMNasdaq : CLNN earningsClene Reports Second Quarter 2023 Financial Results and Operating HighlightsReported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) in patients treated with CNM-Au8 ® in the HEALEY ALS Platform trial Announced publication of the results of the Phase 2 RESCUE ALS study and its open-labelRHEA-AIneutral
08/02/23 7:00 AMNasdaq : CLNN conferencesClene to Present at the Canaccord Genuity 43rd Annual Growth ConferenceClene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, todayRHEA-AIneutral
06/26/23 8:00 AMNasdaq : CLNN clinical trialClene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicineClene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiaryRHEA-AIneutral
06/21/23 9:20 AMNasdaq : CLNN offeringClene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 MillionInvestment led by Vivo Capital with participation from SymBiosis, Acuta Capital Partners, AIGH Capital, Serrado Capital LLC, and other new biotech investors, with support from existing insiders $40 million underwritten public offering with up to an additional potential $130.8 million in proceedsRHEA-AIneutral
06/16/23 8:00 AMNasdaq : CLNN offeringClene Announces Pricing of $40 Million Public OfferingClene Inc. (Nasdaq: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, todayRHEA-AIneutral